Vitamin K5 (hydrochloride) is a naphthoquinones compound, shows trichomonacidal activity in vitro. Vitamin K5(hydrochloride) can be used for the research of anti-infection.

7α-Hydroxycholesterol is a cholesterol oxide and is formed by both enzymatic and non-enzymatic oxidation. 7α-Hydroxycholesterol can be used as a biomarker for lipid peroxidation.

Zuclopenthixol ((Z)-Clopenthixol) is a thioxanthene derivative which acts as a mixed dopamine D1/D2 receptor antagonist.

MTX-531 is a potent and selective inhibitor of EGFR and PI3K with IC50 of 15 nM and 6.4 nM, respectively. MTX-531 represents a unique single-molecule approach to balanced combination therapy that minimizes off-target effects while eliminating the need to optimize the pharmacokinetic profiles of multiple agents.

Epitalon acetate is a synthetic tetrapeptide with anti-aging properties. Epitalon acetate reduces levels of lipid peroxidation products, delays age-related estrous shutdown, and decreases the frequency of bone marrow cell chromosomal aberrations in female mice. It decreases spontaneous mammary gland and ovarian tumor development and metastasis in aged female mice. Epitalon also stimulates melatonin synthesis and normalizes the circadian rhythm.

AK-1690 is the first, potent and selective PROTAC STAT6 degrader with DC50 of 1 nM. AK-1690 displays excellent microsomal and plasma stability, making it a suitable tool compound for in vivo studies.

Compound 23 (LRRK2 inhibitor) is a potent, selective, and CNS penetrant LRRK2 inhibitor with IC50 of 5 nM.

Z6466608628 is a CRBN molecular gluewith EC50 of 0.34 µM. Z6466608628 selectively recruits PPIL4, along with its binding partner DHX40.

CDO1 degrader-1 (compound 8) is a molecular glue degrader that targets cysteine dioxygenase (CDO1).

ZZ1 is a YPEL5-GID/CTLH-dependent BRD4 degrader with CD50 of 502 nM. ZZ1 induces selective degradation of BET proteins (BRD3 and BRD4).

ZZ2 is a YPEL5-GID/CTLH-dependent BRD4 degrader with CD50 of 169 nM.

RGT-587 is a CDK inhibitor and selectively inhibits CDK4 but also has excellent brain penetration.

RGT-419B is a CDK inhibitor and not only actively inhibits CDK2, CDK4 and CDK6, but also demonstrates strong anti-proliferation activities.

Sirukumab (CNTO-136) is a humanized monoclonal anti-IL6 (Interleukin Related) IgG1κ antibody. Sirukumab binds to IL6, preventing IL6-mediated signal transduction and activation of transcriptional activators, thereby blocking the downstream biological effects of IL6. Sirukumab can be used in the study of active lupus nephritis and rheumatoid arthritis.

Elsilimomab (B-E8) is a IgG1 monoclonal antibody against interleukin-6 (IL-6), with a KD of 22 pM and an IC50 of 1.4 nM. Elsilimomab can be used for the research of multiple myeloma, renal cell carcinoma, and rheumatoid arthritis (RA).

Siltuximab is an anti-IL-6 (interleukin-6) monoclonal antibody, and shows antitumor activity. Siltuximab can be used in Multicentric Castleman's Disease (MCD) and COVID-19 research.

Olokizumab (CDP 6038) is a humanized monoclonal antibody targeting the interleukin-6 (IL-6). Olokizumab can be used in research of rheumatoid arthritis (RA).

Clazakizumab is a monoclonal antibody with high affinity and specificity for the IL-6 (interleukin-6) cytokine. Clazakizumab may be helpful in inhibiting the cytokine response to SARS-CoV-2 in COVID-19. Clazakizumab can be used for the research of psoriatic arthritis (PsA) and renal antibody-mediated rejection.